prospective patients have to fall within a pretty strict criteria. I believe that's the only reason IMO. After we see good results, I'm sure the criteria could be broadened. But for now it's a design that should show NVIV can help improve the problem and to allow the FDA to measure the effects / improvement. We all hate waiting but hopefully when we finally start, we hit a homerun. All IMO, GLTA longs and future patients. Keep in mind the best spinal surgeons in the country are involved in this study / trial, patience will be important until we get the first patient.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.